Home Generics Biosimilars Docs & Positions Facts & Figures Press Room Conferences

Press Releases

Top2008

PRESS RELEASE: 24 April 2008

BIOSIMILAR MEDICINES – DEVELOPING MARKET PATHWAYS
THAT BENEFIT PATIENTS IS A SHARED RESPONSIBILITY

EGA Director General Greg Perry congratulated industry and EU medicines regulatory authorities today for further consolidating and developing the EU’s rigorously scientific “biosimilar thinking” during 2007.

PRESS RELEASE: 20 March 2008

THE EGA WELCOMES COMMISSION PROPOSAL AGAINST COUNTERFEITING OF MEDICINES — KEY ACTIONS AND INITIATIVES HIGHLIGHTED

The EGA considers the key proposals to be well designed to target the genuine problems underlying the counterfeiting of medicines.

PRESS RELEASE: 31 January 2008

EGA REITERATES LACK OF RESOURCES FOR NATIONAL REGULATORY AUTHORITIES AS MAJOR BARRIER TO NEW GENERIC MEDICINES

The EGA has reiterated its plea to the National Medicines Authorities to resolve their issues of resources to ensure the rapid and efficient approval of new generic medicines.

PRESS RELEASE: 16 January 2008

EUROPEAN COMMISSION INQUIRY INTO COMPETITION IN THE PHARMACEUTICAL SECTOR

Top2007

EGA NEWS: 29 November 2007

Japanese Genereric Pharmaceutical Manufacturers Association Joins IGPA

Mr Hiroyuki Sawai accepts membership during the 10th Annual IGPA Conference in Miami.
 

PRESS RELEASE: 21 November 2007

PUBLIC INFORMATION LAUNCHED ON BIOSIMILAR MEDICINES

The European Generic medicines Association (EGA) launched its handbook on biosimilar medicines today in Brussels.
 

PRESS RELEASE: 21 November 2007

EGA ELECTS ERIC GORKA AS PRESIDENT: FOCUS WILL BE ON SPEEDING NEW MEDICINES TO MARKET

The European Generic medicines Association (EGA) has elected Eric Gorka, Head Commercial Operations EMEA for Sandoz International, as its new president.
 

PRESS RELEASE: 20 September 2007

EUROPEAN GENERIC MEDICINES INDUSTRY LAUNCHES PACT AGAINST THE COUNTERFEITING OF MEDICINES

The European Generic medicines Association (EGA) has today launched a plan to establish a supply chain integrity pact to fight the counterfeiting of pharmaceuticals.
 

PRESS RELEASE: 3 September 2007

EGA WELCOMES APPROVAL OF FIRST BIOSIMILAR EPOETIN

The new biosimilar medicines, based on one development, have been shown to match a previously approved reference product in terms of quality, safety and efficacy...
 

PRESS RELEASE: 26 June 2007

EGA URGES PRICE DELINKAGE FOR OFF-PATENT MEDICINES AT EU HIGH LEVEL FORUM ON PHARMACEUTICALS

Speaking today at the High Level Forum on Pharmaceuticals, EGA President Emile Loof urged European medicines regulators not to link the price of generic medicines to the price of their corresponding originator products.
 

PRESS RELEASE: 24 May 2007

3rd EGA SOUTH EAST EUROPE SYMPOSIUM:
“Meeting the European Challenge for the National Drug Regulatory Agencies and the Generic Medicines Industry”

Greg Perry praised representatives from thirteen regional medicines agencies for their commitment to understanding EU legislation, and cautioned against adopting provisions which could negativly impact the availability of affordable generic medicines in the region.
 

PRESS RELEASE: 14 May 2007

KEEPING COUNTERFEIT MEDICINES OUT OF THE EU: A PROPORTIONAL AND TARGETED APPROACH REQUIRED

Greg Perry, EGA Director General, presents the generic medicines industry's position on anti-counterfeiting policy at the European Parliament, expressing strong support for Europe’s record of protecting pharmaceutical supplies from counterfeiters.
 

PRESS RELEASE: 3 May 2007

BUILDING A “MARKET PATHWAY” FOR BIOSIMILAR MEDICINES

Now that the science and the regulatory pathway have been established in the EU, industry and regulators must focus on building a “market pathway” for biosimilar medicines.

PRESS RELEASE: 13 February 2007

LACK OF AGENCY RESOURCES DELAYING GENERIC MEDICINES APPLICATIONS

While praising EU regulators for the smooth implementation and running of the new Decentralised Procedure (DCP), the EGA is concerned about the serious lack of resources available to Member State agencies to deal with the regulatory workload.